Works matching IS 2160763X AND DT 2022 AND VI 11 AND IP 10

Results: 13

Issue Information.

Published in:: Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1125, doi. 10.1002/cpdd.832
Publication type:: Article

A Consideration of Fixed Dosing Versus Body Size‐Based Dosing Strategies for Chimeric Antigen Receptor T‐Cell Therapies.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1130, doi. 10.1002/cpdd.1171

By:

He, Jimmy Zhijian;
Wang, Hechuan;
Lim, KyoungSoo;
Ren, Song;
Rollins, Fred;
Vallaster, Markus;
Wong, Ryan;
Stebbings, Richard;
Standifer, Nathan;
Keefe, Robert;
Phipps, Alex;
Gibbs, Megan

Publication type:

Article

Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus–Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1191, doi. 10.1002/cpdd.1154

By:

Han, Kelong;
Theodore, Dickens;
McMullen, Gina;
Swayze, Eric;
McCaleb, Michael;
Billioud, Gaetan;
Wieland, Stefan;
Hood, Steve;
Paff, Melanie;
Bennett, C. Frank;
Kwoh, T. Jesse

Publication type:

Article

Pharmacokinetics, Bioequivalence, and Safety Studies of a Generic Selective Tyrosine Kinase Inhibitor Nilotinib Capsule Versus a Branded Product in Healthy Chinese Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1233, doi. 10.1002/cpdd.1148

By:

Wang, Meng;
Zhu, Yifang;
Huang, Ming;
Wang, Hao;
Zhou, Wenjia;
Lu, Dan;
Zhang, Quanying

Publication type:

Article

Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of EPI‐589 in Healthy Participants.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1136, doi. 10.1002/cpdd.1146

By:

Noda, Naoto;
Hamatani, Tatsuto;
Shibue, Yuta;
Takagaki, Takeshi;
Kitamura, Atsushi;
Haranaka, Miwa;
Ogama, Yoichiro;
Kakuyama, Hiroyoshi

Publication type:

Article

A Phase 1 Thorough QT/QTc Study of Therapeutic and Supratherapeutic Doses of Belumosudil in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1221, doi. 10.1002/cpdd.1142

By:

Schueller, Olivier;
Lohmer, Lauren;
Xue, Hongqi;
Darpo, Borje;
Patel, Jeegar

Publication type:

Article

Pharmacokinetic and Safety Comparison of 2 Afatinib Dimaleate Tablets in Healthy Chinese Volunteers Under Fasted Conditions: A Randomized, Open‐Label, 2‐Period, Single‐Dose Crossover Study.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1177, doi. 10.1002/cpdd.1134

By:

Shi, Ping;
Jiang, Xin;
Tao, Ye;
Li, Ting;
Li, Xin;
Wang, Chenjing;
Liu, Yanping;
Ma, Yaping;
Gao, Xiaomeng;
Cao, Yu

Publication type:

Article

A Reference‐Scaled Average Bioequivalence Study of Azithromycin Tablets Manufactured in China and the United States: An Open‐Label, Randomized, Single‐Dose, 3‐Way Crossover Study in Healthy Chinese Subjects Under Fasted and Fed Conditions

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1147, doi. 10.1002/cpdd.1132

By:

Ge, Beikang;
Li, Cuiyun;
Wei, Hua;
Ding, Yanhua;
Wu, Min;
Liu, Yuwang;
Zhang, Kaiting;
Peng, Ao

Publication type:

Article

Comparative Bioavailability of a Single Dose of Trametinib (TMT212) Containing 9% vs 11% Dimethyl Sulfoxide in Randomized Healthy Volunteers to Assess Long‐Term Storage at Room Temperature.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1203, doi. 10.1002/cpdd.1129

By:

Tan, Eugene Y.;
Chiparus, Ovidiu;
Choudhury, Somesh;
Kim, Christina;
Lau, Mike;
Ziltener, Christoph;
Ilankumaran, Palanichamy

Publication type:

Article

The Safety, Toleration, and Pharmacokinetics of Two Intravenous Voriconazole Formulations in Healthy Chinese Volunteers After Increasing Dose Administrations.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1211, doi. 10.1002/cpdd.1126

By:

Chen, Gang;
Wang, Zejuan;
Liu, Xiaona;
Zhang, Yanan;
Li, Min;
Du, Aihua;
Zhen, Haiqing;
Wang, Xiaolin;
Zhang, Dan;
Zhang, Mengke;
Zang, Siqi;
Zhang, Lina;
Zhu, Huiting;
Wang, Jin

Publication type:

Article

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1165, doi. 10.1002/cpdd.1110

By:

Li, Xiaoyan;
Shelton, Mark J;
Wang, Jing;
Meade, Julie;
Ruiz‐Soto, Rodrigo

Publication type:

Article

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of Youkenafil Hydrochloride, a Phosphodiesterase Type 5 Inhibitor, in Healthy Chinese Male Volunteers.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1184, doi. 10.1002/cpdd.1108

By:

Liang, Beibei;
Wang, Jin;
Bai, Nan;
Chi, Yulong;
Wang, Rui;
Cai, Yun

Publication type:

Article

Pharmacokinetics and Bioequivalence of Single‐Oral‐Dose Linagliptin: A Randomized, 2‐Period Crossover Trial in Chinese Healthy Subjects Under Fasting and Fed Conditions.

Published in:

Clinical Pharmacology in Drug Development, 2022, v. 11, n. 10, p. 1157, doi. 10.1002/cpdd.1104

By:

Li, Yan;
Zhang, Xueyuan;
Qi, Lu;
Tong, Yuanxu;
Bai, Haihong;
Liu, Ju;
Liu, Ying;
Chen, Youli;
Wang, Xinghe

Publication type:

Article